Results 11 to 20 of about 1,127,554 (354)

The Therapeutic Effectiveness of Neoadjuvant Trastuzumab Plus Chemotherapy for HER2-Positive Breast Cancer Can Be Predicted by Tumor-Infiltrating Lymphocytes and PD-L1 Expression

Frontiers in Oncology, 2022
IntroductionNeoadjuvant trastuzumab plus chemotherapy may affect programmed death-ligand 1 (PD-L1) expression and tumor-infiltrating lymphocytes (TILs) in HER2-positive breast cancer.
Mao Shang, Mao Shang, Yajing Chi, Jianbo Zhang, Jin Chang, Hui Yang, Sha Yin, Qiaorui Tan, Xiaochu Man, Huihui Li   +9 more
doaj   +1 more source

Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer

Nature Communications, 2023
Immune checkpoint inhibitors and antiangiogenic agents have shown some activity in patients with late-stage gastric cancer. Here the authors report the results of a phase II trial of neoadjuvant anti-PD1 (camrelizumab), antiangiogenic agent (apatinib ...
Song Li, Wenbin Yu, Fei Xie, Haitao Luo, Zhimin Liu, Weiwei Lv, Duan-bo Shi, Dexin Yu, P. Gao, Cheng Chen, Meng Wei, Wenhao Zhou, Jiaqian Wang, Zhikun Zhao, Xin Dai, Qian Xu, Xue Zhang, Miao Huang, Kai Huang, Jian Wang, Jisheng Li, Lei Sheng, Lian Liu   +22 more
semanticscholar   +1 more source

Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: A prospective multi-center randomized clinical trial.

Annals of Oncology, 2022
BACKGROUND Neoadjuvant therapy is recommended for locally advanced esophageal cancer, but the optimal strategy remains unclear. We aimed to evaluate the safety and efficacy of neoadjuvant chemoradiotherapy (nCRT) vs neoadjuvant chemotherapy (nCT ...
H. Tang, H. Wang, Y. Fang, J. Zhu, J. Yin, Yang Shen, Z. Zeng, D. Jiang, Y. Hou, M. Du, C. Lian, Q. Zhao, H. Jiang, L. Gong, Z. Li, J. Liu, D. Xie, W. Li, C. Chen, B. Zheng, K. Chen, L. Dai, Y. Liao, K. Li, H. C. Li, N. Zhao, L. Tan   +26 more
semanticscholar   +1 more source

Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer [PDF]

, 2015
Neoadjuvant chemotherapy plus trastuzumab (NCT) increases the rate of pathological complete response (pCR) and event-free survival (EFS) compared to neoadjuvant chemotherapy (NC) alone in women with HER2 positive breast cancer (BC).
Ades, F, Ahmed, R, Asher, R, Beresford, M, De Azambuja, E, Gojis, O, Howell, SJ, Januszewski, A, Lewanski, C, Lythgoe, D, Macpherson, IRJ, Owadally, W, Palmieri, C, Riddle, P, Shah, D, Stanley, B, Yan, K   +16 more
core   +4 more sources

Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma

Journal for ImmunoTherapy of Cancer, 2022
Background Camrelizumab and chemotherapy demonstrated durable antitumor activity with a manageable safety profile as first-line treatment in patients with advanced esophageal squamous cell carcinoma (ESCC).
Jun Liu, Yang Yang, Zhichao Liu, Xiao-long Fu, X. Cai, Hong-xuan Li, Li Zhu, Yan Shen, Hong Zhang, Yifeng Sun, Hezhong Chen, Bentong Yu, Renquan Zhang, J. Shao, Ming Zhang, Zhigang Li   +15 more
semanticscholar   +1 more source

Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non–Small Cell Lung Cancer

JAMA Oncology, 2023
Key Points Question Does the addition of camrelizumab to neoadjuvant chemotherapy (nab-paclitaxel and platinum) improve the pathologic complete response (pCR) rate among patients with resectable stage IIIA or IIIB non–small cell lung cancer (NSCLC ...
Jie Lei, Jinbo Zhao, Li Gong, Yun-feng Ni, Yong’an Zhou, F. Tian, Honggang Liu, Zhongping Gu, Lijun Huang, Q. Lu, Xiaoping Wang, Jianyong Sun, E. Yang, Tao Wang, D. Zhong, Jian Wang, Zhengwei Zhao, Zhi-gang Liu, Cheng Wang, Xiaojing Wang, Guangyan Lei, Xiaolong Yan, T. Jiang   +22 more
semanticscholar   +1 more source

Comparison of neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable stage III non-small cell lung cancer: a real-world cohort study

Frontiers in Immunology, 2023
BackgroundWe compared the real-world efficacy and safety of neoadjuvant chemoimmunotherapy to chemotherapy alone in patients with stage III non-small-cell lung cancer (NSCLC).Participants and methodsA total of 59 consecutive patients were finally ...
Sihao Zhou, Yi Liu, Kejun Liu, Junkai Zhang, Hanlin Liang, Yingmeng Wu, Hongyu Ye, Yi Liang, Jingjing Zhang, Weizhao Huang   +9 more
doaj   +1 more source

Neoadjuvant PD-1 blockade plus chemotherapy versus chemotherapy alone in locally advanced stage II-III gastric cancer: A single-centre retrospective study

Translational Oncology, 2023
Background: PD-1 blockade has been shown to have promising efficacy and acceptable safety profiles in advanced and metastatic gastric cancer; however, the efficacy and safety of neoadjuvant PD-1 blockade-based immunotherapy plus chemotherapy in locally ...
Xuchen Zhang, Chuantao Zhang, Helei Hou, Yuming Zhang, Peng Jiang, Hai Zhou, Lele Wang, Na Zhou, Xiaochun Zhang   +8 more
doaj   +1 more source

SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial

Journal of Clinical Oncology, 2021
PURPOSE For patients with resectable stage IIIA(N2) non–small-cell lung cancer, neoadjuvant chemotherapy with cisplatin and docetaxel followed by surgery resulted in a 1-year event-free survival (EFS) rate of 48% in the SAKK 16/00 trial and is an ...
S. Rothschild, A. Zippelius, E. Eboulet, S. Savic Prince, D. Betticher, A. Bettini, M. Früh, M. Joerger, D. Lardinois, H. Gelpke, L. Mauti, C. Britschgi, W. Weder, S. Peters, M. Mark, R. Cathomas, A. Ochsenbein, W. Janthur, C. Waibel, N. Mach, P. Froesch, M. Buess, P. Bohanes, G. Godar, C. Rusterholz, Michel Gonzalez, M. Pless   +26 more
semanticscholar   +1 more source

Neoadjuvant Chemotherapy In Stadium Ib3, Iia2 And Iib Cervical Cancer

Andalas Obstetrics and Gynecology Journal, 2023
Aim: This study aimed to describe Paclitaxel-Carboplatin chemotherapy as neoadjuvant chemotherapy in stage IB3, IIA2 and IIB cervical cancer.   Materials and Methods: The review was conducted by collecting journals from previous studies discussing ...
I Gde Sastra GdeSastra Winata
doaj   +1 more source